Morrison v. Federal Bureau of Prisons

District Court, District of Columbia·Decided March 30, 2021·No. Civil Action No. 2019-1838·Published

Opinion

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA

WILLIAM T. MORRISON, JR., Plaintiff,

v. Case No. 19-cv-1838 (CRC)

FEDERAL BUREAU OF PRISONS,

Defendant.

MEMORANDUM OPINION

Federal inmate William T. Morrison, Jr., proceeding pro se, filed suit alleging that the Federal Bureau of Prisons (“BOP”) has mismanaged the treatment of his high cholesterol. He requests a declaratory judgment stating that he is entitled to receive the nutritional supplement Coenzyme Q10 (“CoQ10”) as part of his treatment. Although Morrison’s Amended Complaint is somewhat unclear, the Court construes his claim as challenging his treatment under the Eighth Amendment of the Constitution. The government has moved to dismiss on the merits and on mootness grounds. Alternatively, it seeks a transfer of venue to the district where Morrison was incarcerated when he filed suit. The Court rejects the government’s mootness and venue arguments. But because Morrison has not alleged facts showing that BOP acted with deliberate indifference to his medical needs, the Court will dismiss the case for failure to state an Eighth Amendment violation. I. Background Mr. Morrison has been in BOP custody since February 2016. Am. Comp. at ¶9. When he filed this suit in June 2019, he was housed at FCI Elkton in Ohio. Id. at 12. He now resides at FCI El Reno in Oklahoma. See Notice of Change of Address, ECF. Dkt. No. 35. According

to Morrison’s December 2019 Amended Complaint–––which the Court must accept as true at this stage of the proceedings–––he has “a . . . family history of coronary heart disease, [including] high levels of cholesterol,” and has been prescribed statin drugs to control his cholesterol levels. See Am. Comp. at ¶¶10, 16. However, he complains that he is “highly intolerant to statin medications,” and “suffers from common side effects” including muscle cramps, joint pain, and fatigue. Id. at ¶17. To alleviate these side effects, Morrison states that prison medical staff previously prescribed him CoQ10. Id. at ¶¶19–20. This combination of statins and CoQ10 helped keep his cholesterol in the proper range and lessened the side effects he had previously experienced while on statins alone. Id. at ¶23.

In 2017, Morrison was informed that CoQ10 could no longer be sold at inmate commissaries. Id. at ¶25. Nevertheless, as Morrison was transferred around the federal prison system, BOP approved his requests to maintain access to the supplement. See generally id. at ¶¶30–37. In late 2018, however, Morrison’s authorization for CoQ10 expired and the “FBOP Central Office refused to approve” further requests for CoQ10 submitted by prison medical staff on Morrison’s behalf. Id. at ¶¶38–40. According to medical records that Morrison attached to his Amended Complaint, BOP denied his requests for CoQ10 because, as a nutritional supplement, it is not FDA approved and it has not otherwise proven effective for the treatment of the types of conditions that Morrison reported to prison medical staff. Am. Comp. Ex. F at 1. 1

1 While typically restricted to the pleadings when deciding a motion to dismiss for failure to state a claim under Federal Rule of Civil Procedure 12(b)(6), a court may consider “documents attached as exhibits or incorporated by reference in the complaint.” Hinton v. Corr. Corp. of Am., 624 F. Supp. 2d 45, 46 (D.D.C. 2009) (internal quotation marks omitted); see also Marshall v. Honeywell Technology Solutions, Inc., 536 F. Supp. 2d 59, 65 (D.D.C. 2008) (“[W]here a document is referred to in the complaint and is central to the plaintiff's claim, such a document attached to the motion papers may be considered without converting the motion [to dismiss] to one for summary judgment.”) (internal quotation and citation omitted). Here,

Without the CoQ10, Morrison alleges that the side effects returned and he discontinued taking his statin medication. Id. at ¶41. Morrison attempted to take various statins in 2019 without CoQ10 but again experienced side effects and stopped taking them. See id. at ¶¶43–50.

After filing his initial complaint in this case and due to his reported intolerance to statins, Morrison was prescribed Repatha, an injectable non-statin medication, with approval of BOP’s Central Office. Id. at ¶50; Am. Comp. Ex. G at 1. Morrison acknowledges that the Repatha injections lowered his cholesterol to normal levels. Am. Comp. at ¶50. Two months after beginning the treatments, however, Morrison reported to FCI Elkton medical staff that he was experiencing lower back pain, muscle aches, and plantar fasciitis, which he claims are side effects of the Repatha. Id. (citing Am. Comp. Ex. H.) Prison medical staff treated his pain with a steroid and provided him stretching exercises to relieve the reported plantar fasciitis. Am. Comp. Ex. H. at 1. Morrison also claims in the Amended Complaint that he developed “fatigue” and “unexplained nail fungus” as a result of taking Repatha, but there is no indication in the attached medical records (nor does the Amended Complaint allege) that he brought these issues to the attention of prison medical staff. Am. Comp. at ¶50.

Morrison seeks declaratory judgments that BOP “is obligated to provide adequate medical care to [p]laintiff while he is in [its] care, custody, and control,” that his “[h]igh levels of blood cholesterol [represent] a serious medical need,” and that he has a right to approval of his non-formulary requests for CoQ10 as part of the treatment for his high cholesterol. Id. at 12. The government has moved to dismiss Morrison’s suit for lack of subject matter jurisdiction due

Morrison has attached eight sets of prison medical records as exhibits to his Amended Complaint, which the Court will consider in deciding the present motion.

to mootness and for failure to state a claim. Alternatively, it seeks a transfer of venue to the Southern District of Ohio, where Morrison was housed when he filed suit. II. Analysis Morrison’s complaint does not cite a specific cause of action supporting his claim of mistreatment and is somewhat unclear as to the basis for his suit. See Am. Comp. at 1–12. The Court will nonetheless construe his complaint liberally due to his pro se status. See, e.g., Sanchez-Mercedes v. Bureau of Prisons, 453 F. Supp. 3d 404, 415–16 (D.D.C. 2020). Because the relief Morrison requests is equitable and makes express reference to his “serious medical need[s]” (a phrase taken from Eighth Amendment caselaw), see Am. Comp. at 12, the Court construes Morrison’s complaint as seeking a declaratory judgment vindicating his Eighth Amendment right to be free from cruel and unusual punishment. So read, the Court has subject matter jurisdiction under 28 U.S.C. § 1331 as Morrison’s claim “aris[es] under the Constitution.” See Simmat v. U.S. Bureau of Prisons, 413 F.3d 1225, 1232 (10th Cir. 2005) (holding, in the context of an Eighth Amendment claim for equitable relief due to denial of medical treatment, that “Section 1331 [] provides jurisdiction for the exercise of the traditional powers of equity in actions arising under” the Eighth Amendment). 2 A. Mootness The government moves to dismiss the action on the grounds that the suit is moot because Morrison is now receiving medication which keeps his cholesterol within normal levels. See Mot. to Dismiss at 5–6. However, while Morrison’s initial complaint focused on the treatment of

2 Morrison also correctly notes that the waiver of sovereign immunity in the Administrative Procedure Act, 5 U.S.C. § 702, would apply to such a suit. Simmat, 413 F.3d at 1233; see also Chamber of Commerce v. Reich, 74 F.3d 1322, 1329 (D.C. Cir. 1996) (“The APA's waiver of sovereign immunity applies to any suit whether under the APA or not.”).

Free access — add to your briefcase to read the full text and ask questions with AI

Morrison v. Federal Bureau of Prisons, (D.D.C. 2021).

Morrison v. Federal Bureau of Prisons (Morrison v. Federal Bureau of Prisons) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Estelle v. Gamble
429 U.S. 97 (Supreme Court, 1976)
Helling v. McKinney
509 U.S. 25 (Supreme Court, 1993)
Simmat v. United States Bureau of Prisons
413 F.3d 1225 (Tenth Circuit, 2005)
Baker v. District of Columbia
326 F.3d 1302 (D.C. Circuit, 2003)
Darnell Cooper and Anthony Davis v. Michael Casey
97 F.3d 914 (Seventh Circuit, 1996)
Chance v. Armstrong
143 F.3d 698 (Second Circuit, 1998)
Farmer v. Brennan
511 U.S. 825 (Supreme Court, 1994)
Banks v. York
515 F. Supp. 2d 89 (District of Columbia, 2007)
Marshall v. Honeywell Technology Solutions, Inc.
536 F. Supp. 2d 59 (District of Columbia, 2008)
Hinton v. Corrections Corp. of America
624 F. Supp. 2d 45 (District of Columbia, 2009)
Chandler v. Stover
211 F. Supp. 3d 289 (District of Columbia, 2016)
Timothy Barr v. Rebecca Pearson
909 F.3d 919 (Eighth Circuit, 2018)